Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...
Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...
Pathological cardiac remodeling in response to sustained pressure overload is a pivotal process in the progression of heart failure (HF), yet the underlying molecular mechanisms remain incompletely understood, limiting therapeutic development. Here, we identify serine/threonine kinase 39 (STK39) ...